CLINICAL TRIALS PROFILE FOR SENSIPAR
✉ Email this page to a colleague
All Clinical Trials for Sensipar
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00132431 ↗ | START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism | Completed | Amgen | Phase 4 | 2004-07-01 | The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary hyperparathyroidism (HPT). |
| NCT00135304 ↗ | ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism | Completed | Amgen | Phase 4 | 2005-08-01 | The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P) product. |
| NCT00189501 ↗ | A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD) | Completed | Amgen | 2004-12-01 | Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters | |
| NCT00195936 ↗ | Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets | Completed | Children's Mercy Hospital Kansas City | Phase 1 | 2005-06-01 | This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion. |
| NCT00345839 ↗ | E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events | Completed | Amgen | Phase 3 | 2006-08-22 | The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (HPT) who are receiving dialysis. |
| NCT00395902 ↗ | Post Transplant Study | Completed | Amgen | 2005-08-01 | Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Sensipar
Condition Name
Clinical Trial Locations for Sensipar
Trials by Country
Clinical Trial Progress for Sensipar
Clinical Trial Phase
Clinical Trial Sponsors for Sensipar
Sponsor Name
